Q2 2026 saw strong adjusted EPS and EBITDA growth, driven by margin recovery, disciplined expense management, and successful launch of Insperity HRScale. Full-year guidance was raised, with continued focus on margin recovery, sales momentum, and managing healthcare cost risks.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.